Glycerol phenylbutyrate approved by the National Medical Products Administration in China for the treatment of Urea Cycle Disorders
Stockholm, June 21, 2023 – Immedica’s partner Hongkong WinHealth Pharma Group Co.Ltd has announced that glycerol phenylbutyrate oral liquid has gained approval for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate synthetase I (CPS), ornithine carbamoyltransferase (OTC), Citrullinemia type 1, argininosuccinuria, argininemia and hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Glycerol phenylbutyrate must be used with